|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 328.16 USD | -0.93% |
|
-2.93% | -17.48% |
| 27/01 | Intellia gets FDA nod to resume one gene therapy trial after safety pause | RE |
| 20/01 | RBC Cuts Price Target on Alnylam Pharmaceuticals to $465 From $500, Keeps Outperform Rating | MT |
| Capitalization | 4.34TCr 3.67TCr 3.36TCr 3.19TCr 5.92TCr 3,92800Cr 6.18TCr 39TCr 15TCr 1,89100Cr 16TCr 16TCr 6,80700Cr | P/E ratio 2025 * |
139x | P/E ratio 2026 * | 47.8x |
|---|---|---|---|---|---|
| Enterprise value | 4.17TCr 3.53TCr 3.24TCr 3.07TCr 5.69TCr 3,78000Cr 5.95TCr 38TCr 15TCr 1,82000Cr 16TCr 15TCr 6,55100Cr | EV / Sales 2025 * |
11.1x | EV / Sales 2026 * | 7.27x |
| Free-Float |
99.2% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Alnylam Pharmaceuticals, Inc.
| 1 day | -0.93% | ||
| 1 week | -2.93% | ||
| Current month | -2.93% | ||
| 1 month | -22.33% | ||
| 3 months | -25.87% | ||
| 6 months | -24.58% | ||
| Current year | -17.48% |
| 1 week | 326.51 |  | 355.49 |
| 1 month | 326.51 | | 409.58 |
| Current year | 326.51 | | 427.05 |
| 1 year | 205.87 | | 495.55 |
| 3 years | 141.98 | | 495.55 |
| 5 years | 117.58 | | 495.55 |
| 10 years | 31.38 | | 495.55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 63 | 01/01/2022 | |
Jeffrey Poulton
DFI | Director of Finance/CFO | 58 | 13/08/2019 |
| Chief Tech/Sci/R&D Officer | - | 01/04/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Dennis Ausiello
BRD | Director/Board Member | 80 | 23/04/2012 |
Amy Schulman
CHM | Chairman | 65 | 05/01/2023 |
David Pyott
BRD | Director/Board Member | 72 | 18/12/2015 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | 0.00% | 5.08% | 1 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.93% | -2.93% | +18.82% | +48.52% | 4.34TCr | |
| +3.66% | +2.03% | +20.48% | +211.52% | 95TCr | |
| +0.93% | +5.61% | +56.73% | +46.87% | 58TCr | |
| +2.01% | +0.19% | +17.22% | +53.94% | 39TCr | |
| -0.64% | +1.63% | +23.32% | +25.27% | 37TCr | |
| +1.82% | +10.57% | +39.70% | +15.38% | 30TCr | |
| +0.89% | +3.71% | +21.59% | +33.23% | 30TCr | |
| +0.57% | +4.66% | +23.89% | +51.27% | 30TCr | |
| +5.29% | -20.04% | -53.01% | -38.83% | 21TCr | |
| +4.49% | +12.41% | +30.93% | +57.51% | 21TCr | |
| Average | +1.81% | +1.53% | +19.97% | +50.47% | 36.41TCr | |
| Weighted average by Cap. | +2.07% | +2.52% | +24.52% | +80.67% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 377.44Cr 319.5Cr 292.83Cr 277.34Cr 514.98Cr 34TCr 538.42Cr 3.4TCr 1.35TCr 16TCr 1.42TCr 1.39TCr 59TCr | 554.6Cr 469.47Cr 430.28Cr 407.52Cr 756.7Cr 50TCr 791.14Cr 5TCr 1.98TCr 24TCr 2.08TCr 2.04TCr 87TCr |
| Net income | 32Cr 27Cr 25Cr 23Cr 43Cr 2.87TCr 45Cr 285.17Cr 112.89Cr 1.38TCr 118.62Cr 116.18Cr 4.97TCr | 93Cr 79Cr 72Cr 69Cr 127.36Cr 8.46TCr 133.15Cr 841.59Cr 333.17Cr 4.07TCr 350.07Cr 342.86Cr 15TCr |
| Net Debt | -162.6Cr -137.64Cr -126.15Cr -119.48Cr -221.86Cr -15TCr -231.95Cr -1.47TCr -580.38Cr -7.09TCr -609.81Cr -597.26Cr -26TCr | -303.93Cr -257.27Cr -235.8Cr -223.32Cr -414.68Cr -28TCr -433.55Cr -2.74TCr -1.08TCr -13TCr -1.14TCr -1.12TCr -48TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/26/06 | 328.16 $ | -0.93% | 14,76,914 |
| 05/26/05 | 331.24 $ | -5.89% | 26,20,979 |
| 04/26/04 | 351.96 $ | +0.05% | 17,79,461 |
| 03/26/03 | 351.80 $ | +3.74% | 21,52,860 |
| 02/26/02 | 339.11 $ | +0.31% | 19,11,150 |
Delayed Quote Nasdaq, February 07, 2026 at 02:30 am IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ALNY Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition